163 related articles for article (PubMed ID: 19460435)
21. Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age.
van der Kolk DM; de Bock GH; Leegte BK; Schaapveld M; Mourits MJ; de Vries J; van der Hout AH; Oosterwijk JC
Breast Cancer Res Treat; 2010 Dec; 124(3):643-51. PubMed ID: 20204502
[TBL] [Abstract][Full Text] [Related]
22. Altered expression of genes involved in progesterone biosynthesis, metabolism and action in endometrial cancer.
Sinreih M; Hevir N; Rižner TL
Chem Biol Interact; 2013 Feb; 202(1-3):210-7. PubMed ID: 23200943
[TBL] [Abstract][Full Text] [Related]
23. Analysis of breast cancer susceptibility genes BRCA1 and BRCA2 in Thai familial and isolated early-onset breast and ovarian cancer.
Patmasiriwat P; Bhothisuwan K; Sinilnikova OM; Chopin S; Methakijvaroon S; Badzioch M; Padungsutt P; Vattanaviboon P; Vattanasapt V; Szabo C; Saunders GF; Goldgar D; Lenoir GM
Hum Mutat; 2002 Sep; 20(3):230. PubMed ID: 12203997
[TBL] [Abstract][Full Text] [Related]
24. 17beta-hydroxysteroid dehydrogenases in human breast cancer.
Nagasaki S; Miki Y; Akahira J; Suzuki T; Sasano H
Ann N Y Acad Sci; 2009 Feb; 1155():25-32. PubMed ID: 19250189
[TBL] [Abstract][Full Text] [Related]
25. Abnormal expression of 17beta-hydroxysteroid dehydrogenases in breast cancer predicts late recurrence.
Gunnarsson C; Olsson BM; Stål O;
Cancer Res; 2001 Dec; 61(23):8448-51. PubMed ID: 11731426
[TBL] [Abstract][Full Text] [Related]
26. Germline RAD51C mutations in ovarian cancer susceptibility.
Coulet F; Fajac A; Colas C; Eyries M; Dion-Minière A; Rouzier R; Uzan S; Lefranc JP; Carbonnel M; Cornelis F; Cortez A; Soubrier F
Clin Genet; 2013 Apr; 83(4):332-6. PubMed ID: 22725699
[TBL] [Abstract][Full Text] [Related]
27. Genetic variants and haplotype analyses of the ZBRK1/ZNF350 gene in high-risk non BRCA1/2 French Canadian breast and ovarian cancer families.
Desjardins S; Belleau P; Labrie Y; Ouellette G; Bessette P; Chiquette J; Laframboise R; Lépine J; Lespérance B; Pichette R; Plante M; ; Durocher F
Int J Cancer; 2008 Jan; 122(1):108-16. PubMed ID: 17764113
[TBL] [Abstract][Full Text] [Related]
28. Expression of 17beta-hydroxysteroid dehydrogenases and other estrogen-metabolizing enzymes in different cancer cell lines.
Smuc T; Rizner TL
Chem Biol Interact; 2009 Mar; 178(1-3):228-33. PubMed ID: 19022235
[TBL] [Abstract][Full Text] [Related]
29. Estrogen and androgen-converting enzymes 17β-hydroxysteroid dehydrogenase and their involvement in cancer: with a special focus on 17β-hydroxysteroid dehydrogenase type 1, 2, and breast cancer.
Hilborn E; Stål O; Jansson A
Oncotarget; 2017 May; 8(18):30552-30562. PubMed ID: 28430630
[TBL] [Abstract][Full Text] [Related]
30. Pathways of adipose tissue androgen metabolism in women: depot differences and modulation by adipogenesis.
Blouin K; Nadeau M; Mailloux J; Daris M; Lebel S; Luu-The V; Tchernof A
Am J Physiol Endocrinol Metab; 2009 Feb; 296(2):E244-55. PubMed ID: 18984855
[TBL] [Abstract][Full Text] [Related]
31. BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families.
Antoniou AC; Durocher F; Smith P; Simard J; Easton DF;
Breast Cancer Res; 2006; 8(1):R3. PubMed ID: 16417652
[TBL] [Abstract][Full Text] [Related]
32. Recent insight on the control of enzymes involved in estrogen formation and transformation in human breast cancer.
Pasqualini JR; Chetrite GS
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):221-36. PubMed ID: 15860265
[TBL] [Abstract][Full Text] [Related]
33. Clinical impact of unclassified variants of the BRCA1 and BRCA2 genes.
Akbari MR; Zhang S; Fan I; Royer R; Li S; Risch H; McLaughlin J; Rosen B; Sun P; Narod SA
J Med Genet; 2011 Nov; 48(11):783-6. PubMed ID: 21965345
[TBL] [Abstract][Full Text] [Related]
34. Mutation analysis of the BCCIP gene for breast cancer susceptibility in breast/ovarian cancer families.
Bonache S; Gutierrez-Enriquez S; Tenés A; Masas M; Balmaña J; Diez O
Gynecol Oncol; 2013 Nov; 131(2):460-3. PubMed ID: 23911796
[TBL] [Abstract][Full Text] [Related]
35. Novel germline BRCA1 and BRCA2 mutations in breast and breast/ovarian cancer families from the Czech Republic.
Machackova E; Damborsky J; Valik D; Foretova L
Hum Mutat; 2001 Dec; 18(6):545. PubMed ID: 11748848
[TBL] [Abstract][Full Text] [Related]
36. Characterization of BRCA1 and BRCA2 variants found in a Norwegian breast or ovarian cancer cohort.
Jarhelle E; Riise Stensland HM; Mæhle L; Van Ghelue M
Fam Cancer; 2017 Jan; 16(1):1-16. PubMed ID: 27495310
[TBL] [Abstract][Full Text] [Related]
37. Identification of chemically diverse, novel inhibitors of 17β-hydroxysteroid dehydrogenase type 3 and 5 by pharmacophore-based virtual screening.
Schuster D; Kowalik D; Kirchmair J; Laggner C; Markt P; Aebischer-Gumy C; Ströhle F; Möller G; Wolber G; Wilckens T; Langer T; Odermatt A; Adamski J
J Steroid Biochem Mol Biol; 2011 May; 125(1-2):148-61. PubMed ID: 21300150
[TBL] [Abstract][Full Text] [Related]
38. Synergistic control of sex hormones by 17β-HSD type 7: a novel target for estrogen-dependent breast cancer.
Wang X; Gérard C; Thériault JF; Poirier D; Doillon CJ; Lin SX
J Mol Cell Biol; 2015 Dec; 7(6):568-79. PubMed ID: 25966904
[TBL] [Abstract][Full Text] [Related]
39. Androgen inactivation and steroid-converting enzyme expression in abdominal adipose tissue in men.
Blouin K; Richard C; Brochu G; Hould FS; Lebel S; Marceau S; Biron S; Luu-The V; Tchernof A
J Endocrinol; 2006 Dec; 191(3):637-49. PubMed ID: 17170221
[TBL] [Abstract][Full Text] [Related]
40. Germline mutations in RAD51C in Jewish high cancer risk families.
Kushnir A; Laitman Y; Shimon SP; Berger R; Friedman E
Breast Cancer Res Treat; 2012 Dec; 136(3):869-74. PubMed ID: 23117857
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
